Sarepta Enters Strategic Relationship With Aldevron For Supply Of Plasmid DNA

( - Sarepta Therapeutics, Inc. ( SRPT ) announced a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta's needs for its gene therapy clinical trials and commercial supply. Aldevron will provide GMP-grade plasmid for Sarepta's micro-dystrophin Duchenne muscular dystrophy gene therapy program and Limb-girdle muscular dystrophy programs, as well as plasmid source material for future gene therapy programs.

Aldevron supplies plasmid DNA and gene editing enzymes to biopharmaceutical researchers developing advanced gene-based medicines. The company employs a team of 270 across its three locations in Fargo, North Dakota, Madison, Wisconsin, and Freiburg, Germany.

Read the original article on RTTNews (

For comments and feedback: contact

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story